Camille L Bedrosian
Chief Medical Officer; Director · 6 filings · Latest: Sep 10, 2026
Amylyx Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
AMLX | Camille L Bedrosian | Chief Medical Officer | Sep 10, 2026 | Sale | $32.40 | 10,028 | $324.9K | 278,064 | |
AMLX | Bedrosian Camille L | — | Sep 10, 2026 | Proposed Sale | $32.40 | 10,028 | $324.9K | — | |
RYTM | CAMILLE L BEDROSIAN | — | Mar 4, 2026 | Proposed Sale | $90.62 | 64,540 | $5.8M | — | |
AMLX | Camille L Bedrosian | Chief Medical Officer | Mar 2, 2026 | Sale | $14.58 | 6,461 | $94.2K | 169,295 | |
RYTM | CAMILLE L BEDROSIAN | — | Mar 3, 2026 | Proposed Sale | $90.52 | 35,460 | $3.2M | — | |
AMLX | Bedrosian Camille L | — | Mar 2, 2026 | Proposed Sale | $14.58 | 6,461 | $94.2K | — | |
AMLX | Bedrosian Camille L | — | Dec 1, 2025 | Proposed Sale | $14.35 | 6,580 | $94.4K | — |